Home Medizin Merck sucht nach GLP-1-Medikamenten mit Vorteilen, die über die Gewichtsabnahme hinausgehen

Merck sucht nach GLP-1-Medikamenten mit Vorteilen, die über die Gewichtsabnahme hinausgehen

von NFI Redaktion

(Reuters) – Merck & Co is seeking GLP-1 treatments with benefits beyond just weight loss, CEO Robert Davis said at a conference on Thursday.

Newer diabetes and weight loss drugs of the GLP-1 class such as Wegovy and Ozempic from Novo Nordisk, as well as Mounjaro and Zepbound from Eli Lilly, are expected to collectively generate annual sales of over $100 billion by the end of the decade.

Merck’s experimental drug Efinopegdutide, which belongs to the GLP-1 class and is being developed for the treatment of non-alcoholic steatohepatitis (NASH), also showed a „compelling“ weight loss benefit.

Demonstrating benefits beyond weight loss may make it easier to obtain reimbursement for the drugs, Davis said.

„I think everyone recognizes that weight management is hard to reimburse. But if you can show cardiovascular outcomes, if you can show diabetes outcomes, for which you are gradually seeing data, if you can see benefits in fatty liver disease,“ „That’s an area where we see opportunities,“ he said.

GLP-1 drugs, which help control blood sugar levels and trigger a feeling of fullness, are also being investigated to see if they can improve health in other ways.

Data from last year suggests that Semaglutide, the active ingredient in Wegovy and Ozempic, may also reduce the risk of stroke or heart attack and delay the progression of kidney disease in diabetic patients.

Bloomberg was the first to report on Davis‘ comments on Thursday.

(Reporting by Pratik Jain and Sriparna Roy in Bengaluru; Editing by Pooja Desai and Sriraj Kalluvila)

Related Posts

Adblock Detected

Please support us by disabling your AdBlocker extension from your browsers for our website.